Cero Therapeutics Reports Board and Officer Changes
Ticker: CEROW · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1870404
| Field | Detail |
|---|---|
| Company | Cero Therapeutics Holdings, INC. (CEROW) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, compensation
Related Tickers: CERO
TL;DR
Cero Therapeutics (CERO) filed an 8-K detailing leadership changes and compensation updates.
AI Summary
Cero Therapeutics Holdings, Inc. filed an 8-K on May 30, 2025, reporting changes in its board of directors and executive officers, along with updates to compensatory arrangements. The company, formerly known as Phoenix Biotech Acquisition Corp., is involved in biological products.
Why It Matters
Changes in a company's leadership and compensation structures can signal shifts in strategy or operational focus, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes and updates to compensatory arrangements can introduce uncertainty regarding the company's future direction and stability.
Key Players & Entities
- Cero Therapeutics Holdings, Inc. (company) — Registrant
- Phoenix Biotech Acquisition Corp. (company) — Former company name
- May 30, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors or executive officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not detail the specific individuals or roles affected in the provided text.
What is the nature of the updates to compensatory arrangements?
The filing mentions updates to 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature of these arrangements in the provided text.
When was the company formerly known as Phoenix Biotech Acquisition Corp.?
The company's name change from Phoenix Biotech Acquisition Corp. to Cero Therapeutics Holdings, Inc. occurred on June 30, 2021.
What is Cero Therapeutics Holdings, Inc.'s Standard Industrial Classification (SIC) code?
Cero Therapeutics Holdings, Inc. has a SIC code of 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the fiscal year end for Cero Therapeutics Holdings, Inc.?
The fiscal year end for Cero Therapeutics Holdings, Inc. is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding CERO THERAPEUTICS HOLDINGS, INC. (CEROW).